Fig. 22.1 Conceptual framework for understandig barriers to adherence (McCue et al. [9] with permission) It is important to recognize that adherence is dynamic and must be viewed not only…
Fig. 30.1 Number of publications per year from January 1994 to December 2013 30.1.3 Patient-Reported Outcome Instruments HRQL is typically measured using Clinical Outcome Assessment (COA) tools, i.e., instruments designed…
Type of sexual difficulty Men 16–24 years Men 25–34 years Women 16–24 years Women 25–34 years Lacked interest in having sex 11.5 % 14.5 % 24.8 % 31.9 % Lacked…
Fig. 16.1 Proportion of major bone sarcoma groups by age (SEER, 2000–2011) Fig. 16.2 Bone incidence by type and age from SEER (2000–2011) The clinical significance of bone sarcomas in…
Survivors of AYA cancer No history of cancer p-value Adjusted expenditures [95 % CI] Adjusted expenditures [95 % CI] All sources of payment $7,417 [6,133, 8,700] $4,247 [4,142, 4,352]…
Fig. 10.1 Age-dependent incidence of melanoma. Age-dependent incidence of in-situ and invasive melanoma (top left). Age-dependent incidence of melanoma by sex (top right). Age-dependent incidence of AYA melanoma in face/scalp/neck…
Family Family support networks Direct Indirect Direct Indirect Median $3503 $23,130 $575 $3215 Range $754–$51,906 $1259–$48,236 $6–$10,315 $58–$29,061 Reference 46 47 In Canadian dollars It has been suggested that…
© Springer International Publishing 2017Archie Bleyer, Ronald Barr, Lynn Ries, Jeremy Whelan and Andrea Ferrari (eds.)Cancer in Adolescents and Young AdultsPediatric Oncology10.1007/978-3-319-33679-4_31 31. Palliative Care Karen Wasilewski-Masker1 , Tracy Howk2 , Erin Connelly2 , Sergey Postovsky3 , Pamela Brill2 , Kate Carlson Wrammert4 and Rathi Pillai4 (1) The Aflac Cancer &…
Therapeutic exposure Potential late effect Vincristine, vinblastine Peripheral neuropathy, Raynaud’s phenomenon Corticosteroids Cataracts, osteopenia, osteoporosis, avascular necrosis Mercaptopurine Hepatic dysfunction, veno-occlusive disease Methotrexate (Systemic) osteopenia, osteoporosis, renal dysfunction, hepatic dysfunction…
Fig. 26.1 Potential problems encountered by AYA during and following treatment for cancer according to the International Classification of Functioning, Disability and Health 26.2 Body Structure and Function Impairments of…
